MX2015003541A - Metodos para identificar los anticuerpos con inmunogenia reducida. - Google Patents

Metodos para identificar los anticuerpos con inmunogenia reducida.

Info

Publication number
MX2015003541A
MX2015003541A MX2015003541A MX2015003541A MX2015003541A MX 2015003541 A MX2015003541 A MX 2015003541A MX 2015003541 A MX2015003541 A MX 2015003541A MX 2015003541 A MX2015003541 A MX 2015003541A MX 2015003541 A MX2015003541 A MX 2015003541A
Authority
MX
Mexico
Prior art keywords
reduced immunogenicity
methods
identifying antibodies
antibody
identifying
Prior art date
Application number
MX2015003541A
Other languages
English (en)
Inventor
Fiona A Harding
Olivia Jennifer Razo
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of MX2015003541A publication Critical patent/MX2015003541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La divulgación describe los métodos para identificar una variante de un anticuerpo de referencia con inmunogenia reducida con respecto al anticuerpo de referencia. La divulgación además describe las variantes de un anticuerpo anti-TNF-a de referencia que tiene una inmunogenia reducida con respecto al anticuerpo anti-TNF-a de referencia.
MX2015003541A 2012-09-19 2013-09-18 Metodos para identificar los anticuerpos con inmunogenia reducida. MX2015003541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261703170P 2012-09-19 2012-09-19
PCT/US2013/060480 WO2014047222A2 (en) 2012-09-19 2013-09-18 Methods for identifying antibodies with reduced immunogenicity

Publications (1)

Publication Number Publication Date
MX2015003541A true MX2015003541A (es) 2015-10-26

Family

ID=49304336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003541A MX2015003541A (es) 2012-09-19 2013-09-18 Metodos para identificar los anticuerpos con inmunogenia reducida.

Country Status (27)

Country Link
US (1) US9279016B2 (es)
EP (2) EP3211006A3 (es)
JP (1) JP2015537190A (es)
KR (1) KR20150056788A (es)
CN (1) CN104704000A (es)
AU (1) AU2013318147B2 (es)
BR (1) BR112015005857A2 (es)
CA (1) CA2885422A1 (es)
CY (1) CY1118893T1 (es)
DK (1) DK2897978T3 (es)
ES (1) ES2621285T3 (es)
HK (1) HK1211306A1 (es)
HR (1) HRP20170937T1 (es)
HU (1) HUE032569T2 (es)
IL (1) IL237833A0 (es)
IN (1) IN2015DN01967A (es)
LT (1) LT2897978T (es)
MX (1) MX2015003541A (es)
NZ (1) NZ705606A (es)
PL (1) PL2897978T3 (es)
PT (1) PT2897978T (es)
RS (1) RS56093B1 (es)
RU (1) RU2648141C2 (es)
SG (1) SG11201502094TA (es)
SI (1) SI2897978T1 (es)
TW (1) TWI519646B (es)
WO (1) WO2014047222A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
WO2018162376A1 (en) * 2017-03-07 2018-09-13 F. Hoffmann-La Roche Ag Method for discovery of alternative antigen specific antibody variants
TW202039554A (zh) * 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
WO2021005607A1 (en) * 2019-07-09 2021-01-14 National Institute For Biotechnology In The Negev Ltd. Antibodies with reduced immunogenicity
CA3151450A1 (en) 2019-09-30 2021-04-08 Matthias Schneider Protein binders to irhom2 epitopes
FR3104582A1 (fr) * 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Variants de l’adalimumab au potentiel immunogène réduit
CN113125714B (zh) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 一种人类免疫缺陷病毒抗体检测试剂盒及其应用
WO2021147642A1 (en) * 2020-01-20 2021-07-29 Bio-Thera Solutions, Ltd. Methods, models and systems related to antibody immunogenicity
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
BR112023017035A2 (pt) 2021-03-01 2024-02-06 New York Soc For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surger Anticorpos humanizados contra irhom2, ácido nucleico, uso do anticorpo, composição farmacêutica, composição, método de tratamento e kit terapêutico
WO2022207652A1 (en) 2021-03-29 2022-10-06 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024033362A1 (en) 2022-08-08 2024-02-15 Atb Therapeutics Humanized antibodies against cd79b

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0189330B1 (en) 1985-01-25 1992-12-02 The Kitasato Institute Antitumor antibiotics and their production
US5264357A (en) 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
PT1135498E (pt) 1998-11-18 2008-04-30 Genentech Inc Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
EP1218543A2 (en) 1999-09-29 2002-07-03 Solexa Ltd. Polynucleotide sequencing
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6897023B2 (en) 2000-09-27 2005-05-24 The Molecular Sciences Institute, Inc. Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6956114B2 (en) 2001-10-30 2005-10-18 '454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2004029284A2 (en) 2002-09-30 2004-04-08 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
PT1951759E (pt) 2005-11-12 2010-04-01 Lilly Co Eli Anticorpos anti-egfr
CA2696210A1 (en) 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
SA111320266B1 (ar) * 2010-03-11 2015-06-21 رينات نيوروساينس كوربوريشن أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
TW201209063A (en) * 2010-08-13 2012-03-01 Roche Glycart Ag Anti-tenascin-C A2 antibodies and methods of use
AU2011318574B2 (en) * 2010-10-20 2016-03-03 Oxford Biotherapeutics Ltd. Antibodies

Also Published As

Publication number Publication date
WO2014047222A9 (en) 2014-06-26
HRP20170937T1 (hr) 2017-11-03
KR20150056788A (ko) 2015-05-27
CA2885422A1 (en) 2014-03-27
AU2013318147A1 (en) 2015-03-19
EP2897978B1 (en) 2017-03-22
EP2897978A2 (en) 2015-07-29
NZ705606A (en) 2018-05-25
HK1211306A1 (en) 2016-05-20
SI2897978T1 (sl) 2017-05-31
LT2897978T (lt) 2017-06-12
DK2897978T3 (en) 2017-05-15
US9279016B2 (en) 2016-03-08
WO2014047222A2 (en) 2014-03-27
TWI519646B (zh) 2016-02-01
HUE032569T2 (en) 2017-09-28
JP2015537190A (ja) 2015-12-24
EP3211006A2 (en) 2017-08-30
PT2897978T (pt) 2017-05-22
RS56093B1 (sr) 2017-10-31
RU2648141C2 (ru) 2018-03-22
US20140227251A1 (en) 2014-08-14
CY1118893T1 (el) 2018-01-10
CN104704000A (zh) 2015-06-10
IN2015DN01967A (es) 2015-08-14
ES2621285T3 (es) 2017-07-03
WO2014047222A3 (en) 2014-10-23
IL237833A0 (en) 2015-05-31
BR112015005857A2 (pt) 2017-08-08
PL2897978T3 (pl) 2017-08-31
EP3211006A3 (en) 2017-11-08
AU2013318147B2 (en) 2018-01-04
SG11201502094TA (en) 2015-04-29
TW201418469A (zh) 2014-05-16
RU2015111671A (ru) 2016-11-10

Similar Documents

Publication Publication Date Title
MX2015003541A (es) Metodos para identificar los anticuerpos con inmunogenia reducida.
CO7151521A2 (es) Anticuerpos anti-fcrn
HK1204571A1 (en) Protease-regulated antibodies
IL228001A0 (en) Antibodies to 70cd
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
IL230719A0 (en) highly galactosylated antibodies
EP2722343A4 (en) ANTI-ERBB3 ANTIBODIES
IL235059A0 (en) Anti–il–23p19 antibodies
EP2844290A4 (en) NOVEL ANTIBODIES
GB201103836D0 (en) Conjugation process
EP2832855A4 (en) NEW ANTI-SIGLEC ANTIBODY-15
AU2013316100A1 (en) Antibody evolution immunogens
MX370649B (es) Proceso para la preparacion de teneligliptina.
MX350335B (es) Anticuerpos que enlazan alfa-v beta-8 integrina.
HK1210186A1 (en) Anti-h7cr antibodies h7cr
WO2014033158A3 (en) Pcsk9 peptide vaccine
EP2804876A4 (en) NEW ANTIBODIES
HK1211694A1 (en) Methods for identifying hiv neutralizing antibodies hiv
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies